Indications and uses
Temporarily relieves: muscle pain minor arthritis pain headache pain of colds
Temporarily relieves: muscle pain minor arthritis pain headache pain of colds
adults and children 12 years and over: see instructions in red box for opening packet place 1 powder on the tongue and swallow with or without water repeat every 4-6 hours, while symptoms persist do not take more than 4 powders in 24 hours children under 12 years: ask a doctor
Drug Facts
Temporarily relieves:
Children and teenagers who have or are recovering from chickenpox or flu-like symptoms should not use this product. When using this product, if changes in behavior with nausea and vomiting occur, consult a doctor because these symptoms could be an early sign of Reye's syndrome, a rare but serious illness.
Aspirin may cause a severe allergic reaction which may include:
This product contains an NSAID, which may cause severe stomach bleeding. The chance is higher if you:
Do not use if you are allergic to aspirin or any other pain reliever/fever reducer.
Ask a doctor or pharmacist before use if you are taking a prescription drug for
When using this product limit use of caffeine-containing drugs, foods, or drinks, because too much caffeine may cause nervousness, irritability, sleeplessness, and occasionally rapid heartbeat
If pregnant or breast-feeding, ask a health professional before use. It is especially important not to use aspirin during the last 3 months of pregnancy unless definitely directed to do so by a doctor because it may cause problems in the unborn child or complications during delivery.
Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.
adults and children 12 years and over:
children under 12 years: ask a doctor
acesulfame potassium, citric acid, flavor, glucose, sucralose
1-888-998-7436 (Mon-Fri 9AM-5PM MDT)
| Do not use if pouch is torn or open |
distributed by
URGENT Rx®
Breakthrough Products, Inc.
Denver, CO 80202
| Class | Version | Type | Effective |
|---|---|---|---|
| ASPIRIN Pharmacologic Class Indexing | 3 | Indexing - Pharmacologic Class | 20191108 |
| CAFFEINE Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 51596-008-01 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-0cf4-f424-e053-dadaa90a57ce | Ache and Pain Relief to Go ™ |
| 51596-008-05 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-0cf4-f424-e053-dadaa90a57ce | Ache and Pain Relief to Go ™ |
| 51596-008-10 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-0cf4-f424-e053-dadaa90a57ce | Ache and Pain Relief to Go ™ |
| 51596-008-12 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-0cf4-f424-e053-dadaa90a57ce | Ache and Pain Relief to Go ™ |
| 51596-008-24 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-0cf4-f424-e053-dadaa90a57ce | Ache and Pain Relief to Go ™ |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 51596-008-01 | Ache and Pain Relief to Go | 1 in 1 POUCH | POWDER | 1 | 4 | |
| 51596-008-05 | Ache and Pain Relief to Go | 5 in 1 BOX | POWDER | 5 | 4 | |
| 51596-008-10 | Ache and Pain Relief to Go | 1 in 1 PACKET | POWDER | 1 | 4 | |
| 51596-008-10 | Ache and Pain Relief to Go | 10 in 1 BOX | POWDER | 10 | 4 | |
| 51596-008-12 | Ache and Pain Relief to Go | 12 in 1 BOX | POWDER | 12 | 4 | |
| 51596-008-24 | Ache and Pain Relief to Go | 24 in 1 BOX | POWDER | 24 | 4 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| aspirin | ACTIVE INGREDIENT | R16CO5Y76E | 4 | |
| caffeine | ACTIVE INGREDIENT | 3G6A5W338E | 4 | |
| aspirin | ACTIVE MOIETY | R16CO5Y76E | 4 | |
| caffeine | ACTIVE MOIETY | 3G6A5W338E | 4 | |
| acesulfame potassium | INACTIVE INGREDIENT | 23OV73Q5G9 | 4 | |
| anhydrous citric acid | INACTIVE INGREDIENT | XF417D3PSL | 4 | |
| dextrose | INACTIVE INGREDIENT | IY9XDZ35W2 | 4 | |
| sucralose | INACTIVE INGREDIENT | 96K6UQ3ZD4 | 4 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 51596-008 | 51596-008-01, 51596-008-05, 51596-008-12, 51596-008-24, 51596-008-10 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| aspirin | R16CO5Y76E | ACTIB |
| caffeine | 3G6A5W338E | ACTIB |
| acesulfame potassium | 23OV73Q5G9 | IACT |
| anhydrous citric acid | XF417D3PSL | IACT |
| dextrose | IY9XDZ35W2 | IACT |
| sucralose | 96K6UQ3ZD4 | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| anhydrous citric acid | ANHYDROUS CITRIC ACID | XF417D3PSL | FILM / SUBLINGUAL | 11 mg | ||
| acesulfame potassium | ACESULFAME POTASSIUM | 23OV73Q5G9 | POWDER, FOR SUSPENSION / ORAL | 45 mg/5ml | ||
| anhydrous citric acid | ANHYDROUS CITRIC ACID | XF417D3PSL | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 414 mg | ||
| dextrose | DEXTROSE | IY9XDZ35W2 | LOZENGE / BUCCAL | NA | ||
| anhydrous citric acid | ANHYDROUS CITRIC ACID | XF417D3PSL | SPRAY / NASAL | 5 mg | ||
| anhydrous citric acid | ANHYDROUS CITRIC ACID | XF417D3PSL | CLOTH / TOPICAL | 4.2 mg | ||
| dextrose | DEXTROSE | IY9XDZ35W2 | TABLET, EXTENDED RELEASE / ORAL | 103.95 mg | ||
| anhydrous citric acid | ANHYDROUS CITRIC ACID | XF417D3PSL | SUSPENSION/ DROPS / OPHTHALMIC | 0.05 %w/v | ||
| sucralose | SUCRALOSE | 96K6UQ3ZD4 | TABLET, CHEWABLE / ORAL | 28 mg | ||
| sucralose | SUCRALOSE | 96K6UQ3ZD4 | TABLET, EXTENDED RELEASE / ORAL | 1 mg | ||
| sucralose | SUCRALOSE | 96K6UQ3ZD4 | SUSPENSION / ORAL | 383 mg | ||
| anhydrous citric acid | ANHYDROUS CITRIC ACID | XF417D3PSL | SUSPENSION, EXTENDED RELEASE / ORAL | 62 mg | ||
| anhydrous citric acid | ANHYDROUS CITRIC ACID | XF417D3PSL | TABLET / BUCCAL | 30 mg | ||
| sucralose | SUCRALOSE | 96K6UQ3ZD4 | TABLET, FOR SUSPENSION / ORAL | 65 mg | ||
| sucralose | SUCRALOSE | 96K6UQ3ZD4 | GRANULE, FOR SUSPENSION / ORAL | 23 mg | ||
| dextrose | DEXTROSE | IY9XDZ35W2 | TABLET, COATED / ORAL | 132 mg | ||
| sucralose | SUCRALOSE | 96K6UQ3ZD4 | GUM, CHEWING / BUCCAL | 70 mg | ||
| acesulfame potassium | ACESULFAME POTASSIUM | 23OV73Q5G9 | FILM / SUBLINGUAL | 5 mg | ||
| anhydrous citric acid | ANHYDROUS CITRIC ACID | XF417D3PSL | LOTION / TOPICAL | 211 mg | ||
| sucralose | SUCRALOSE | 96K6UQ3ZD4 | TABLET / ORAL | 45 mg | ||
| sucralose | SUCRALOSE | 96K6UQ3ZD4 | TABLET, ORALLY DISINTEGRATING / ORAL | 60 mg | ||
| anhydrous citric acid | ANHYDROUS CITRIC ACID | XF417D3PSL | SOLUTION/ DROPS / AURICULAR (OTIC) | 1 mg | ||
| anhydrous citric acid | ANHYDROUS CITRIC ACID | XF417D3PSL | TABLET, EXTENDED RELEASE / ORAL | 312 mg | ||
| acesulfame potassium | ACESULFAME POTASSIUM | 23OV73Q5G9 | TABLET, ORALLY DISINTEGRATING / ORAL | 24 mg | ||
| acesulfame potassium | ACESULFAME POTASSIUM | 23OV73Q5G9 | TABLET / SUBLINGUAL | 13 mg | ||
| dextrose | DEXTROSE | IY9XDZ35W2 | TROCHE / ORAL | 903.5 mg | ||
| dextrose | DEXTROSE | IY9XDZ35W2 | TABLET / SUBLINGUAL | 115.78 mg | ||
| sucralose | SUCRALOSE | 96K6UQ3ZD4 | FILM, SOLUBLE / ORAL | 33 mg | ||
| acesulfame potassium | ACESULFAME POTASSIUM | 23OV73Q5G9 | SOLUTION / DENTAL | 0.12 %w/w | ||
| acesulfame potassium | ACESULFAME POTASSIUM | 23OV73Q5G9 | TABLET / ORAL | 111 mg | ||
| anhydrous citric acid | ANHYDROUS CITRIC ACID | XF417D3PSL | SUSPENSION / ORAL | 400 mg | ||
| anhydrous citric acid | ANHYDROUS CITRIC ACID | XF417D3PSL | CREAM / TOPICAL | 1 mg | ||
| acesulfame potassium | ACESULFAME POTASSIUM | 23OV73Q5G9 | TABLET, EFFERVESCENT / ORAL | 4 mg | ||
| sucralose | SUCRALOSE | 96K6UQ3ZD4 | GRANULE / ORAL | 5.4 mg | ||
| anhydrous citric acid | ANHYDROUS CITRIC ACID | XF417D3PSL | SHAMPOO / TOPICAL | 0.07 %w/w | ||
| anhydrous citric acid | ANHYDROUS CITRIC ACID | XF417D3PSL | INJECTION, SOLUTION / SUBCUTANEOUS | 25 mg | ||
| sucralose | SUCRALOSE | 96K6UQ3ZD4 | SPRAY, METERED / NASAL | 2 mg | ||
| dextrose | DEXTROSE | IY9XDZ35W2 | SOLUTION / INTRAVENOUS | 5.05 %w/v | ||
| anhydrous citric acid | ANHYDROUS CITRIC ACID | XF417D3PSL | AEROSOL, FOAM / TOPICAL | 6 mg | ||
| anhydrous citric acid | ANHYDROUS CITRIC ACID | XF417D3PSL | PASTE / ORAL | 26 mg | ||
| anhydrous citric acid | ANHYDROUS CITRIC ACID | XF417D3PSL | SUSPENSION/ DROPS / ORAL | 15 mg | ||
| anhydrous citric acid | ANHYDROUS CITRIC ACID | XF417D3PSL | SYRUP / ORAL | 268 mg | ||
| acesulfame potassium | ACESULFAME POTASSIUM | 23OV73Q5G9 | TROCHE / ORAL | 26 mg | ||
| anhydrous citric acid | ANHYDROUS CITRIC ACID | XF417D3PSL | INJECTION, SOLUTION, CONCENTRATE / INTRAVENOUS | 81 mg | ||
| dextrose | DEXTROSE | IY9XDZ35W2 | INJECTION / INTRAMUSCULAR | 5 %w/v | ||
| acesulfame potassium | ACESULFAME POTASSIUM | 23OV73Q5G9 | LOZENGE / ORAL | 120 mg | ||
| anhydrous citric acid | ANHYDROUS CITRIC ACID | XF417D3PSL | INJECTION / INFILTRATION | 0.02 %w/v | ||
| anhydrous citric acid | ANHYDROUS CITRIC ACID | XF417D3PSL | AEROSOL / TOPICAL | 0.08 %w/w | ||
| anhydrous citric acid | ANHYDROUS CITRIC ACID | XF417D3PSL | TABLET, EFFERVESCENT / ORAL | 840 mg | ||
| dextrose | DEXTROSE | IY9XDZ35W2 | SOLUTION / ORAL | 2489 mg/5ml | ||
| anhydrous citric acid | ANHYDROUS CITRIC ACID | XF417D3PSL | OIL / TOPICAL | 2 mg | ||
| sucralose | SUCRALOSE | 96K6UQ3ZD4 | POWDER, FOR SOLUTION / ORAL | 414 mg | ||
| anhydrous citric acid | ANHYDROUS CITRIC ACID | XF417D3PSL | POWDER, FOR SUSPENSION / ORAL | 570 mg | ||
| dextrose | DEXTROSE | IY9XDZ35W2 | INJECTION / INTRASPINAL | 75 mg | ||
| acesulfame potassium | ACESULFAME POTASSIUM | 23OV73Q5G9 | TABLET, CHEWABLE / ORAL | 15 mg | ||
| anhydrous citric acid | ANHYDROUS CITRIC ACID | XF417D3PSL | SPRAY, METERED / NASAL | 1.2 mg/1ml | ||
| anhydrous citric acid | ANHYDROUS CITRIC ACID | XF417D3PSL | CAPSULE / ORAL | 131 mg | ||
| dextrose | DEXTROSE | IY9XDZ35W2 | TABLET, DELAYED RELEASE / ORAL | NA | ||
| dextrose | DEXTROSE | IY9XDZ35W2 | SPRAY, METERED / NASAL | 50 mg | ||
| anhydrous citric acid | ANHYDROUS CITRIC ACID | XF417D3PSL | INJECTION, SOLUTION / INTRAVENOUS | 772 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 11bf8091-bb9d-48a5-ba03-a6886a0da329 | bc31d987-e59d-4386-b421-199ae11d4024 | 2014-10-08 | Warnings | 11bf8091-bb9d-48a5-ba03-a6886a0da329 bc31d987-e59d-4386-b421-199ae11d4024 |
Adverse event summaries are temporarily unavailable. Other product information remains available.